



(a)




(b)



**S. Figure 1. Cell viability and microscope images of CRC 1 and CRC 2 with drug treatment.** (a) Dose-Response Curves for CRC 1 and CRC 2 exposed to varying concentrations of 5-FU, Oxaliplatin, and Irinotecan. (b) Microscope images of CRC 1 and CRC 2's response to different drug treatments.

(a)




**S. Figure 2. Size variability in CRC 1 and CRC 2 over a 32-Day period drug treatment. 5-Fu, Oxaliplatin and combination of 5-Fu + Oxaliplatin were treated during experiments.**

(a)

**CRC1**

**CRC2**



(b)

**CRC1**

**CRC2**

Tissue

Organoid


Tissue

Organoid



H&E

EpCAM

CK20



**S. Figure 3. Comparative cellular and staining imaging of CRC1 and CRC2.** (a) CRC1 and CRC2 cell cultures grown in petri dishes. (b) Hematoxylin and eosin stain and immunohistochemical staining of CRC1 and CRC2.



**S. Figure 4. Analysis of patterning variability with and without VT-MAP structural elements and sequential images of stable patterning phases.** (a) Comparison of patterning outcomes based on the presence of mesh elements in VT-MAP and variations in contact angle. The presence of a mesh-assisted structure coupled with a lower contact angle facilitates stable patterning. (b) Time-lapse imagery illustrating the patterning process.